$46.64 -0.2 -0.4%
Last Trade - 22/01/21
| Market Cap | ÂŁ2.26bn |
| Enterprise Value | ÂŁ1.36bn |
| Revenue | ÂŁ182.7m |
| Position in Universe | 1737th / 6630 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 25.4 | 14.1 | 6.16 | 35.4 | 54.6 | 44.7 | 260.4 | 143.9 | +11.9% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | April 16, 1992 |
| Public Since | June 19, 2013 |
| No. of Shareholders: | 9 |
| No. of Employees: | 1,171 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 66,373,320 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 60 Binney St, CAMBRIDGE, 02142-1512, United States |
| Web | http://www.bluebirdbio.com |
| Phone | +1 339 4999300 |
| Contact | Ingrid Goldberg (VP, Investor Relations) |
| Auditors | Ernst & Young LLP |
As of 22/01/21, shares in bluebird bio Inc are trading at $46.64, giving the company a market capitalisation of ÂŁ2.26bn. This share price information is delayed by 15 minutes.
Shares in bluebird bio Inc are currently trading at $46.64 and the price has moved by -48.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the bluebird bio Inc price has moved by -55.54% over the past year.
Of the analysts with advisory recommendations for bluebird bio Inc, there are there are currently 8 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for bluebird bio Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
bluebird bio Inc is scheduled to issue upcoming financial results on the following dates:
bluebird bio Inc does not currently pay a dividend.
bluebird bio Inc does not currently pay a dividend.
bluebird bio Inc does not currently pay a dividend.
To buy shares in bluebird bio Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in bluebird bio Inc are currently trading at $46.64, giving the company a market capitalisation of ÂŁ2.26bn.
Here are the trading details for bluebird bio Inc:
Based on an overall assessment of its quality, value and momentum, bluebird bio Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in bluebird bio Inc are currently priced at $46.64. At that level they are trading at 71.98% discount to the analyst consensus target price of 0.00.
Analysts covering bluebird bio Inc currently have a consensus Earnings Per Share (EPS) forecast of -9.895 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like bluebird bio Inc. Over the past six months, the relative strength of its shares against the market has been -38.96%. At the current price of $46.64, shares in bluebird bio Inc are trading at -16.09% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for bluebird bio Inc.
bluebird bio Inc's management team is headed by:
Here are the top five shareholders of bluebird bio Inc based on the size of their shareholding:
